| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
UTRECHT, The Netherlands and CAMBRIDGE, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) (Merus, the Company, we, or our), an oncology company developing innovative, full-length multispecific antibodies and antibody drug conjugates (Biclonics®, Triclonics® and ADClonics®), today announced the acceptance of two abstracts on petosemtamab, a Biclonics® targeting EGFR and LGR5, for presentation at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held in Boston, Massachusetts on October 22-26, 2025.
Initial interim data from the phase 2 trial evaluating petosemtamab in combination with standard chemotherapy in 1L and 2L metastatic colorectal cancer (mCRC), and as monotherapy in heavily pretreated (3L+) mCRC will be presented in a plenary session by Dr. Moh'd Khushman M.D., Washington University School of Medicine, St. Louis, MO. Merus will also present a poster regarding the preclinical evaluation of petosemtamab on cancer stem cells.
Posted In: MRUS
